# Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

> **NCT06953726** · PHASE4 · NOT_YET_RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 10000 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT06953726
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2032-10-04
- **Final completion:** 2033-10-03
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06953726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06953726, "Comparing the Safety and Efficacy of Apixaban and Rivaroxaban". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06953726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*